Viracta Therapeutics VIRX Stock
Viracta Therapeutics Price Chart
Viracta Therapeutics VIRX Financial and Trading Overview
| Viracta Therapeutics stock price | 0.0098 USD |
| Previous Close | 1.55 USD |
| Open | 1.55 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 1.49 - 1.68 USD |
| 52 Week Range | 0.88 - 5.75 USD |
| Volume | 307.35K USD |
| Avg. Volume | 236.92K USD |
| Market Cap | 61.07M USD |
| Beta (5Y Monthly) | -0.313622 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.8 USD |
VIRX Valuation Measures
| Enterprise Value | 10.2M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.5588236 |
| PEG Ratio (5 yr expected) | -0.01 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.3372582 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.196 |
Trading Information
Viracta Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.313622 |
| 52-Week Change | -38.37% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.75 USD |
| 52 Week Low | 0.88 USD |
| 50-Day Moving Average | 1.41 USD |
| 200-Day Moving Average | 2.39 USD |
VIRX Share Statistics
| Avg. Volume (3 month) | 236.92K USD |
| Avg. Daily Volume (10-Days) | 202.98K USD |
| Shares Outstanding | 38.41M |
| Float | 23.56M |
| Short Ratio | 1.46 |
| % Held by Insiders | 6.68% |
| % Held by Institutions | 60.92% |
| Shares Short | 693.2K |
| Short % of Float | 2.29% |
| Short % of Shares Outstanding | 1.79% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 285:1000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -35.54% |
| Return on Equity (ttm) | -74.40% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -52086000 USD |
| Net Income Avi to Common (ttm) | -50860000 USD |
| Diluted EPS (ttm) | -1.3 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 80.33M USD |
| Total Cash Per Share (mrq) | 2.09 USD |
| Total Debt (mrq) | 25.54M USD |
| Total Debt/Equity (mrq) | 49.97 USD |
| Current Ratio (mrq) | 7.157 |
| Book Value Per Share (mrq) | 1.189 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -35434000 USD |
| Levered Free Cash Flow (ttm) | -17594624 USD |
Profile of Viracta Therapeutics
| Country | United States |
| State | CA |
| City | Cardiff-by-the-Sea |
| Address | 2533 South Coast Highway 101 |
| ZIP | 92007 |
| Phone | 858 400 8470 |
| Website | https://www.viracta.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 39 |
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Q&A For Viracta Therapeutics Stock
What is a current VIRX stock price?
Viracta Therapeutics VIRX stock price today per share is 0.0098 USD.
How to purchase Viracta Therapeutics stock?
You can buy VIRX shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Viracta Therapeutics?
The stock symbol or ticker of Viracta Therapeutics is VIRX.
Which industry does the Viracta Therapeutics company belong to?
The Viracta Therapeutics industry is Biotechnology.
How many shares does Viracta Therapeutics have in circulation?
The max supply of Viracta Therapeutics shares is 39.66M.
What is Viracta Therapeutics Price to Earnings Ratio (PE Ratio)?
Viracta Therapeutics PE Ratio is now.
What was Viracta Therapeutics earnings per share over the trailing 12 months (TTM)?
Viracta Therapeutics EPS is -1.1 USD over the trailing 12 months.
Which sector does the Viracta Therapeutics company belong to?
The Viracta Therapeutics sector is Healthcare.
Viracta Therapeutics VIRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23615.22 USD — |
<0.01
|
2.37B USD — | 23567.86 USD — | 23665.15 USD — | — - | 2.37B USD — |
| US Tech Global Select Market Com NQGS | 11568.61 USD — |
+0.02
|
— — | 11548.2 USD — | 11595.66 USD — | — - | — — |
| US Tech Biotechnology NBI | 5802.34 USD — |
-0.71
|
— — | 5792.54 USD — | 5835.34 USD — | — - | — — |
| US Tech Health Care IXHC | 1204.69 USD — |
-0.61
|
— — | 1203.88 USD — | 1210.54 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}